|
1.
|
|
|
2.
|
|
12 p, 600.5 KB |
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
/
Carlo-Stella, Carmelo (Humanitas Research Hospital (Itàlia)) ;
Zinzani, Pier Luigi (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Sureda, Anna (Hospital Universitari de Bellvitge) ;
Araújo, Luis (Universitário de Coimbra) ;
Casasnovas, Olivier (CHU Dijon Bourgogne) ;
Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ;
Yeh, Su-Peng (China Medical University Hospital) ;
Bouabdallah, Krimo (University Hospital of Bordeaux) ;
Cartron, Guillaume (Centre Hospitalier Universitaire Montpellier) ;
Kim, Won Seog (Samsung Medical Center) ;
Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ;
Koh, Youngil (Seoul National University Hospital) ;
Re, Alessandro (ASST Spedali Civili Brescia) ;
Alves, Daniela (Centro Hospitalar Universitário Lisboa Norte) ;
Chamuleau, Martine (Vrije Universiteit Amsterdam) ;
Le Gouill, Steven (Institut Curie) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Moreira, Ilídia (Portuguese Institute of Oncology of Porto) ;
van der Poel, Marjolein W. M. (Maastricht University Medical Center) ;
Abbadessa, Giovanni (Sanofi) ;
Meng, Robin (Sanofi) ;
Ji, Ran (Sanofi) ;
Lépine, Lucie (Sanofi) ;
Saleem, Rao (Sanofi) ;
Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ;
Universitat Autònoma de Barcelona
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). [...]
2022 -  10.1002/hon.3089
Hematological Oncology, Vol. 41 (october 2022) , p. 108-119
|
|
|
3.
|
|
4 p, 973.0 KB |
Long-term follow-up of recovered MPN patients with COVID-19
/
Barbui, Tiziano (Papa Giovanni XXIII Hospital) ;
Iurlo, Alessandra (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Masciulli, Arianna (Papa Giovanni XXIII Hospital) ;
Carobbio, Alessandra (Papa Giovanni XXIII Hospital) ;
Ghirardi, Arianna (Papa Giovanni XXIII Hospital) ;
Rossi, Giuseppe (Spedali Civili) ;
Harrison, Claire (Guy's and St. Thomas' NHS Foundation Trust) ;
Alvarez-Larran, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Elli, Elena María (Ospedale San Gerardo (Itàlia)) ;
Kiladjian, Jean-Jaques (Hospital Saint-Louis) ;
Gasior Kabat, Mercedes (Hospital Universitario La Paz (Madrid)) ;
Marin Sanchez, Alberto (Complejo Hospitalario Universitario de Albacete) ;
Palandri, Francesca (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Andrade-Campos, Marcio Miguel (Hospital del Mar (Barcelona, Catalunya)) ;
Vannucchi, Alessandro Maria (University of Florence) ;
Carreño-Tarragona, Gonzalo (Hospital Universitario 12 de Octubre (Madrid)) ;
Papadopoulos, Petros (Hospital Clínico San Carlos (Madrid)) ;
Quiroz Cervantes, Keina (Hospital Universitario de Móstoles (Madrid)) ;
Foncillas, Maria Angeles (Hospital Universitario Infanta Leonor) ;
Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ;
Sagues Serrano, Miguel (Hospital de Sant Joan Despí Moisès Broggi) ;
Rumi, Elisa (University of Pavia) ;
Osorio, Santiago (Hospital General Universitario Gregorio Marañón) ;
Benevolo, Giulia (AOU Città della Salute e della Scienza di Torino) ;
Patriarca, Andrea (AOU Maggiore della Carità) ;
Navas Elorza, Begoña (Hospital Moncloa) ;
Garcia-Gutierrez, Valentín (Hospital Universitario Ramón y Cajal (Madrid)) ;
Magro Mazo, Elena (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid)) ;
Lunghi, Francesca (IRCCS Ospedale San Raffaele) ;
Bonifacio, Massimiliano (Ospedale Policlinico "G.B. Rossi". Borgo Roma) ;
De Stefano, Valerio (Fondazione Policlinico "A. Gemelli" IRCCS) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Lopez Abadia, Emma (Hospital General de Elche (Alicante)) ;
Angona, Anna (Hospital Universitari de Girona Doctor Josep Trueta) ;
Xicoy Cirici, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruggeri, Marco (Ospedale San Bortolo) ;
Koschmieder, Steffen (RWTH Aachen University) ;
Sobas, Marta Anna (Wroclaw Medical University) ;
Cuevas, Beatriz (Hospital Universitario de Burgos) ;
Cattaneo, Daniele (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Daffini, Rosa (Spedali Civili) ;
Bellini, Marta (ASST Papa Giovanni XXIII) ;
Curto-Garcia, Natalia (Guy's and St. Thomas' NHS Foundation Trust) ;
Garrote, Marta (Hospital Clínic i Provincial de Barcelona) ;
Cavalca, Fabrizio (Hematology Division and Bone Marrow Transplant Unit. San Gerardo Hospital. ASST Monza) ;
Benajiba, Lina (Hospital Saint-Louis) ;
Bellosillo Paricio, Beatriz (Hospital del Mar (Barcelona, Catalunya)) ;
Guglielmelli, Paola (University of Florence) ;
Borsani, Oscar (University of Pavia) ;
Betti, Silvia (Fondazione Policlinico "A. Gemelli" IRCCS) ;
Salmoiraghi, Silvia (ASST Papa Giovanni XXIII) ;
Rambaldi, Alessandro (Università degli Studi di Milano) ;
Universitat Autònoma de Barcelona
2021 - 10.1038/s41408-021-00509-0
Blood Cancer Journal, Vol. 11 Núm. 6 (june 2021) , p. 115
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
10 p, 911.0 KB |
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
/
Davies, A. (Cancer Research UK Centre) ;
Trask, P. (Genentech Inc.) ;
Demeter, J. (Semmelweis University) ;
Florschütz, A. (Städtisches Klinikum Dessau) ;
Hänel, M. (Klinikum Chemnitz gGmbH) ;
Kinoshita, T. (Aichi Cancer Center Hospital) ;
Pettengell, R. (St George's University) ;
Quach, H. (St Vincent's Hospital (Sydney)) ;
Robinson, S. (Bristol Haematology and Oncology Centre) ;
Sadullah, S. (James Paget Hospital) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Udvardy, M. (Medical and Health Science Centre. University of Debrecen) ;
Witzens-Harig, M. (Uniklinik Heidelberg) ;
Knapp, A. (F. Hoffmann-La Roche Ltd) ;
Liu, W. (F. Hoffmann-La Roche Ltd) ;
Universitat Autònoma de Barcelona
Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. [...]
2020 - 10.1007/s00277-020-04021-6
Annals of Hematology, Vol. 99 Núm. 12 (december 2020) , p. 2837-2846
|
|
|
7.
|
|
10 p, 2.8 MB |
Flexible geoadditive survival analysis of non-Hodgkin lymphoma in Peru
/
Flores, Claudio (Universitat Politècnica de Catalunya. Departament de Estadística) ;
Rodríguez-Girondo, Mar (Universidade de Vigo) ;
Cadarso-Suárez, Carmen (Universidade de Santiago de Compostela. Departamento de Estatística, Análise Matemática e Optimización) ;
Kneib, Thomas (Georg August University. Department of Economics) ;
Gómez Melis, Guadalupe (Universitat Politècnica de Catalunya. Departament de Estadística) ;
Casanova, Luis (Instituto Nacional de Enfermedades Neoplásicas (Lima, Perú))
Knowledge of prognostic factors is an important task for the clinical management of Non Hodgkin Lymphoma (NHL). In this work, we study the variables affecting survival of NHL in Peru by means of geoadditive Cox-type structured hazard regression models while accounting for potential spatial correlations in the survival times. [...]
2012
SORT : statistics and operations research transactions, Vol. 36, Núm. 2 (juliol-desembre 2012) , p. 221-230
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
